We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Clinical Trial Medical-Image Collect-and-Hold System Centralizes Imaging Data

By LabMedica International staff writers
Posted on 20 Aug 2009
A new image management solution has been designed to collect and hold medical images in clinical trials, called iMAS (image management archive system). More...
The iMAS is a cost-effective option for clinical trial sponsors to centralize the collection of the large imaging data sets frequently utilized in clinical trials, while giving them accessibility and secure storage, with minimal investment.

The system was developed by M2S, Inc. (West Lebanon, NH, USA), a global provider of image management services for biopharmaceutical and medical device clinical trials. M2S offers cost-effective medical image management solution for clinical trial sponsors.

"Clinical trial sponsors are facing extraordinary cost pressures in the current economy,” said Wes Chapman, CEO of M2S. "With less time needed for setup, decreased trial complexity, and reduced documentation requirements, an M2S iMAS trial is typically only 20% of the cost of a full clinical trial. This option gives trial sponsors the control and flexibility to adjust a trial and add a blinded radiological review at any point, while simultaneously containing costs.”

While many clinical trials continue to incorporate imaging data for surrogate endpoints, it is not always clear whether image data review and submission will be necessary. However, potentially valuable and expensive imaging data can and probably should still be collected. Sponsors may want to consider using those images for a later submission, subsequent trials or for patient registries, and the risk, cost, and effort of retrospectively collecting images can exceed that of prospective medical image collection.

M2S will customize the iMAS product based on service levels needed for a particular clinical trial--including consultation, project management, and query management. Real-time, web-based reports allow sponsors to see both the status of data gathered as well as access the data anytime, anywhere.

M2S provides medical image data management services across the healthcare continuum based on best-in-class technology and continuous quality improvement processes. M2S clinical trial image-management services include protocol development, electronic image collection, independent review, archive, and real-time web-based data access. M2S clinical data registries provide long-term evaluation of treatment outcomes, benefits, and cost.

Related Links:
M2S


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.